• br Materials and methods br Results br Discussion In the

  2024-06-19

  

  Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi

• The disease stimulatory effects of hyperadiponectinemia in p

  2024-06-19

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• Most studies on d penicillamine induced MG

  2024-06-19

  

  Most studies on d-penicillamine-induced MG were performed before the discovery that some MG patients have anti-MuSK antibodies. After the identification of the present case, we retrospectively tested the stored frozen sera of ten earlier identified d-penicillamine MG patients with anti-AChR CPI-455

• At present drugs that specifically inhibit YAP

  2024-06-18

  

  At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi

• Aurora A or B selective and pan aurora inhibitors have

  2024-06-18

  

  Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas

• Tedizolid The apoptosis promoting Bcl family includes BH onl

  2024-06-18

  

  The apoptosis-promoting Bcl-2 family includes BH3-only proteins (e.g., Bim, Bid and Bad) and multiple-domain proteins (e.g., Bax and Bak). At the time of apoptosis stimulation (e.g., DNA damage), only the BH3-only protein is activated, directly or indirectly promoting Bax/Bak oligomerization, changi

• Thus phosphorylation of p was used to measure the

  2024-06-18

  

  Thus, phosphorylation of p38 was used to measure the intracellular potency of ASK1 inhibitors. In this assay, HEK293/AP-1luc Tirofiban hydrochloride monohydrate expressing human full-length ASK1 were incubated with compound for 18 h and then lysed and the level of phospho-p38 was quantified using th

• These anatomical studies were followed by the first

  2024-06-18

  

  These anatomical studies were followed by the first functional MRI studies of auditory processing in songbirds that were performed in starlings (Van Meir et al., 2005; De Groof et al., 2017; De Groof et al., 2013b) and in zebra finches (Boumans et al., 2008a; Boumans et al., 2007; Boumans et al., 20

• Different antioxidants were described as useful biomarkers

  2024-06-18

  

  Different antioxidants were described as useful biomarkers in monitoring response to treatment in human and veterinary medicine [33,65,66]. In the same line, Thiol and TAC also proved to be useful biomarkers in monitoring the post-ovariohysterectomy period in queens with pyometra, since antioxidants

• VEGFR inhibition using sunitinib does

  2024-06-18

  

  VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons

• Use of RASB is associated

  2024-06-18

  

  Use of RASB is associated with potential concerns about side effects such as acute kidney injury or hyperkalemia, and clinicians are reluctant to prescribe RASB in patients with severe renal dysfunction (estimated GFR Conclusions Conflict of interest Acknowledgement Introduction Renin-an

• wst-1 assay synthesis No starting dose adjustment is

  2024-06-18

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• br Conclusions br Material and methods br Conflicts of inter

  2024-06-18

  

  Conclusions Material and methods Conflicts of interest Acknowledgements Introduction Currently more than 30 human proteins are implicated in a range of degenerative disorders owing to their misfolding and misassembly into various aggregate structures and leading to at least 20 serious

• What is the mechanism by which Wnt

  2024-06-18

  

  What is the mechanism by which Wnt7a-Fz7 signaling enhances AMPAR localization and synaptic strength? Following induction of LTP, the number of AMPARs rapidly increases at extrasynaptic sites (Makino and Malinow, 2009, Yang et al., 2008a) through PKA-dependent phosphorylation of GluA1 at S845 (He et

• To date LOX is the only LOX

  2024-06-18

  

  To date, 12-LOX is the only LOX isoform that has been identified in the platelet [17]. Interestingly, while 12-LOX is highly expressed (∼14000 molecules/platelet) in the platelet, 12(R)-LOX expression is absent in the hematopoietic lineage and has therefore not been reported to be expressed in plate

14345 records 136/957 page Previous Next First page 上5页 136137138139140 下5页 Last page